Psychedelic Alpha: MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics

Today’s announcement perhaps reflects something of an eggshell-treading transition: Lykos has dropped “MAPS” from its name, but perhaps retains a nod to its founder and its nonconformist roots; it’s also sought a relatively conventional form of financing for the first time, a Series A equity round, but highlights the fact that the lead investor, Helena, along with many other participants, are “mission-aligned”.

Originally appearing here (Archived)